Please login to the form below

Not currently logged in
Email:
Password:

India revokes Pfizer's patent on Sutent

Loses patent protection for kidney cancer drug after Cipla and Natco challenge

Pfizer has become the latest Western drugmaker to fall foul of India's increasingly contentious intellectual property (IP) environment, losing patent protection for its kidney cancer drug Sutent.

The country's Patent Office revoked the basic patent for Sutent (sunitinib malate) on the grounds that it did not include an inventive step, backing the position taken up by Indian drugmakers Cipla and Natco Pharma in a legal challenge to Pfizer's IP.

Cipla had argued that the inventiveness of Pfizer's patent was compromised by "structural obviousness", in other words the compound's structure could have been deduced from similar drugs already covered by earlier patents.

Pfizer said immediately it would lodge an appeal against the Patent Office's decision, which is the third defeat for a major pharma company in India in as many weeks, all involving widely-used cancer drugs.

The company sells its Sutent product for 1.96 lakh (about $3,800) for a 45-day course, and Cipla says it will make its Sunitib version available at a 10 per cent discount, according to a LiveMint report.

Last month, Bayer failed in a bid to overturn a compulsory license which removed patent protection for its Nexavar (sorafenib) cancer drug, allowing a cut-price competitor from Natco to enter the market. 

Just a few days before the Nexavar verdict Roche lost a four-year legal dispute with Cipla over patent rights to Tarceva (erlotinib), while Novartis is still in the throes of a long-running legal dispute as it tries to defend blockbuster cancer drug Glivec (imatinib) and is expecting a verdict before the end of this year.

Pfizer had already protected Sutent from a compulsory license challenge in 2008, a year after the company was awarded its patent and launched the product, and in an interview with the Business Standard said the Patent Office's latest action "raised concerns over India's commitment to protect intellectual property".

5th October 2012

From: PME

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Agnitio

Agnitio is a leading supplier of state-of-the-art multichannel communication. Specialists in digital communication tools for the global life sciences industry,...

Latest intelligence

14_ipad_lowres.jpg
Do your customers feel that you’re listening to them?
When answering to data, excellent digital communication can create much stronger relationships between reps and customers....
Mapping content strategies to pharma lifecycle management
In these tough economic times, we should be ramping up our pharma lifecycle management (LCM) strategies. These are well-established strategies for managing and extending the commercial value of products. So...
Back from the future – innovation for pharma
After 5 days of seeing amazing innovations, having discussions about the future of medicine and the practicalities of living on Mars. Plus listening to inspiring speakers from fighter plane-flying physicians...

Infographics